Inhibition of ADAM9 Promotes the Selective Degradation of KRAS and Sensitizes Pancreatic Cancers to Chemotherapy

Scientists identified a disintegrin and metalloproteinase domain (ADAM) 9 as a modulator of PDAC progression via stabilization of wild-type and mutant KRAS proteins.